Related by context. All words. (Click for frequent words.) 74 antibody titers 74 seroprotection 72 virologic failure 71 antibody titer 70 virologic response 69 titers 68 viremia 68 sustained virological response 67 virological response 67 undetectable viral load 66 seropositivity 66 sustained virologic response 66 viral suppression 66 HIV RNA 66 HBeAg seroconversion 66 HPV-#/# 65 viral load 65 HBsAg 65 titer 65 HCV genotype 65 seroconverted 64 virologic 64 definite stent thrombosis 64 complete cytogenetic response 64 virological failure 64 HI titers 64 CR nPR 64 SVR# 63 HIV seroconversion 63 virologic responses 63 mg kg dose 63 HBV DNA 63 undetectable viral loads 63 seropositive 63 CCyR 63 CMV infection 63 undetectable HCV RNA 62 seronegative 62 pCR 62 undetectable HBV DNA 62 ertapenem 62 remission CR 62 TDF FTC 62 palivizumab 62 viral kinetics 62 valacyclovir 62 mcg dose 62 chlamydial infection 62 ipsilateral stroke 62 NNRTI resistance 62 evaluable patients 62 severe rotavirus gastroenteritis 62 vaccinees 62 alanine aminotransferase 62 detectable HCV RNA 62 μg dose 62 serum testosterone 61 transaminase elevations 61 antibody responses 61 leukocyte count 61 dose cohort 61 hemagglutination inhibition 61 postvaccination 61 HBeAg positive patients 61 log# reduction 61 biochemical relapse 61 chlorambucil 61 genotypic resistance 61 cART 61 HIV uninfected 61 trivalent inactivated influenza 61 evaluable subjects 61 Kaplan Meier analysis 61 posaconazole 61 recurrent VTE 61 recurrent genital herpes 61 median CD4 61 antiviral efficacy 61 ALT flares 61 hemoglobin concentrations 61 serum ALT 61 virologic suppression 61 LPV r 61 CIN3 61 CMV disease 61 fosamprenavir 61 rapid virologic response 61 neutralizing antibody 61 ABC/3TC 61 LEXIVA r 61 external genital lesions 61 lymphocytosis 61 neutrophil counts 61 decitabine 60 ribavirin therapy 60 anti HBs 60 hepatitis C genotype 60 tipranavir r 60 BARACLUDE ® 60 undetectable hepatitis C 60 mg/m2 dose 60 seropositive patients 60 CR CRu 60 HBeAg 60 CD4 + cell 60 antiviral therapy 60 HBeAg negative patients 60 Pegasys plus Copegus 60 atazanavir 60 complete cytogenetic 60 symptom onset 60 seroprevalence 60 antiviral activity 60 abacavir lamivudine 60 PASI scores 60 MRSA colonization 60 pegIFN 60 experienced virologic failure 60 iclaprim 60 baseline CD4 60 coinfection 60 cytogenetic response 60 μmol L 60 Peg IFN 60 CANCIDAS 60 HCV antibody 60 HBeAg negative 60 peginterferon 60 dose cohorts 60 cells mcL 60 APTIVUS r 59 severe neutropenia 59 achieved ACR# 59 febrile neutropenia 59 ALT normalization 59 #mg BID [001] 59 patients evaluable 59 mg QD 59 plasma cortisol 59 superinfection 59 IU mL 59 coinfected 59 plasma uric acid 59 adalimumab 59 ALT elevation 59 antiretroviral naive 59 HCV genotype 1 59 Virologic 59 nucleotide analog 59 serum IGF 59 postexposure prophylaxis 59 platelet reactivity 59 Menveo 59 copies ml 59 imipenem 59 timepoints 59 IgM 59 mg ustekinumab 59 posttreatment 59 alanine aminotransferase ALT 59 achieved sustained virologic 59 atazanavir ritonavir 59 % CI #.#-#.# [003] 59 PSA nadir 59 HbA 1c levels 59 pneumococcal vaccination 59 ribavirin RBV 59 serum HBV DNA 59 serum urate 59 log# copies mL 59 REYATAZ r arm 59 tipranavir 59 serologic 59 progression TTP 59 HCV RNA 59 serum urate levels 59 Lupuzor ™ 58 HBV infection 58 HCV 58 IU ml 58 serum concentrations 58 solithromycin 58 spontaneous preterm delivery 58 antibody titres 58 relapsed MM 58 dose cyclophosphamide 58 HPV subtypes 58 genital ulcers 58 HBeAg positive 58 HAART 58 log# 58 peginterferon alfa 2b 58 microg 58 4CMenB 58 peginterferon alfa 2a 58 #mg QD [002] 58 achieved sustained virological 58 ACR# responses 58 posttransplant 58 virologic failures 58 NNRTI resistant virus 58 amoxicillin clavulanate 58 HAART regimens 58 ritonavir boosted 58 PREZISTA r 58 genotype 1b 58 adefovir 58 concomitant antibiotics 58 CRp 58 HCV infected 58 adenoma recurrence 58 CIN2 + 58 Viral load 58 cEVR 58 HBV DNA levels 58 entecavir 58 low expressors 58 nelfinavir 58 glycated hemoglobin levels 58 clodronate 58 intramuscular dose 58 enfuvirtide 58 serum HCV RNA 58 rFSH 58 trimethoprim sulfamethoxazole 58 viraemia 58 NAbs 58 NRTI resistance 58 daunorubicin 58 Cmax 58 potent antiretroviral therapy 58 AST ALT 58 hyperbilirubinemia 58 #mg BID [003] 58 mRCC 58 XIENCE V PROMUS Stent 58 nmol liter 58 neutralizing antibodies 58 sUA 58 seroprotective 58 serum potassium 58 response CCyR 58 latent tuberculosis infection 58 ug dose 58 Vacc 4x 58 CD4 lymphocyte count 58 tipranavir ritonavir 58 viral titers 58 serum cortisol 58 S/GSK# 58 tamoxifen therapy 58 imatinib therapy 58 SCr 58 cervical intraepithelial neoplasia 58 lamivudine 58 preterm deliveries 58 MCyR 58 piperacillin tazobactam 58 hematologic toxicity 58 PegIFN RBV 58 endophthalmitis 58 certolizumab 58 copies mL 58 specific antigen PSA 58 HCV genotypes 58 lymphocyte counts 58 binary restenosis 57 lopinavir r arm 57 SLNB 57 lumbar spine BMD 57 NATRECOR ® 57 transgene expression 57 CD# upregulation 57 aspartate aminotransferase 57 A1c levels 57 follicle stimulating hormone FSH 57 nitazoxanide 57 median PFS 57 XELOX 57 lymphocyte count 57 biochemical recurrence 57 eosinophil count 57 Havrix 57 virologically 57 octreotide LAR 57 serum antibody 57 REYATAZ r 57 revaccination 57 PEG IFN 57 mcg BID 57 immunogenicity 57 heavily pretreated 57 viral loads 57 CD4 cell 57 #mg dose [002] 57 Kaplan Meier estimates 57 tirofiban 57 CIMZIA TM 57 FOLFOX 57 multivariable analysis 57 postintervention 57 rizatriptan 57 lopinavir 57 DAS# CRP 57 null responders 57 Aptivus ® 57 ZOSTAVAX 57 serum IgE 57 serum aminotransferase levels 57 undetectable viral 57 mcg albinterferon alfa 2b 57 mg BID 57 antiretroviral naïve 57 noninferiority 57 BCG vaccination 57 reactogenicity 57 annualized relapse 57 plasma concentrations 57 cervical lesions 57 nonvaccine 57 #mg/m# [001] 57 Subgroup analyzes 57 splenectomized patients 57 CIN2 57 treatment naïve genotype 57 tumor recurrence 57 virologic response EVR 57 treatment naive genotype 57 dosage regimens 57 efavirenz EFV 57 Hb A1C 57 TMC# r 57 timepoint 57 rapid virological response 57 DAS# remission 57 median survivals 57 p = NS 57 elevated ALT 57 quadrivalent vaccine 57 IELT 57 uninfected infants 57 highly immunogenic 57 vertebral fracture 57 humoral responses 57 chronic HBV 57 vicriviroc 57 oral FTY# 57 plasma HCV RNA 57 acute gout flares 57 radezolid 57 fluvastatin 57 docetaxel chemotherapy 57 serum prostate 57 ACR# response 57 Engerix B 57 Telbivudine 57 invasive aspergillosis 57 liver transplant recipients 57 Tmax 57 baseline LDH 57 DLTs 57 GnRH agonist 57 serum creatinine levels 57 pegylated interferon 57 immunological responses 57 oxycodone CR 57 peg IFN 57 SUVmax 57 platelet counts 57 varicella zoster virus VZV 57 Virologic failure 57 HSCT 57 CAIV T 57 pyrazinamide 57 protease inhibitors PIs 57 nucleoside naive patients 57 anemia hemoglobin 57 im peramivir 57 plus dexamethasone 57 HIV seronegative 57 doxorubicin docetaxel 56 thrombocytopenic 56 plasma pharmacokinetics 56 mcg kg 56 neutrophil count 56 liver histology 56 Neisseria gonorrhoeae 56 hours postdose 56 tuberculin skin testing 56 mIU ml 56 troponin T 56 parasitaemia 56 HCV infection 56 varicella vaccine 56 complete remissions 56 #mg QD [001] 56 ASCUS 56 hemagglutination inhibition HAI 56 endometrial carcinoma 56 oral allopurinol 56 neoadjuvant chemotherapy 56 TEAEs 56 Chlamydia infection 56 recurrent UTI 56 interquartile range 56 protease inhibitor PI 56 VAX# 56 VZV 56 mg/m2/day 56 CD4 counts 56 baseline HbA1c 56 clinico pathological 56 nanomolar 56 evaluable 56 galiximab 56 REYATAZ R 56 docetaxel 56 unboosted 56 indinavir 56 HER2 expression 56 locoregional recurrence 56 virus HBV 56 BCG vaccinated 56 imatinib 56 dosing cohorts 56 bacteremia 56 mIU mL 56 serum phosphate 56 nevirapine NVP 56 fluoroquinolone resistance 56 discontinuations due 56 cidofovir 56 varicella 56 multivariate Cox 56 pomalidomide 56 NRTI 56 leukemia ALL 56 g dL 56 oral diclofenac 56 HCV replicon 56 pneumococcal infection 56 inactivated poliovirus vaccine 56 caspofungin 56 lamivudine monotherapy 56 cells μL 56 steroid dexamethasone 56 mcg mL 56 IFN alpha 56 AZT zidovudine Retrovir 56 EDSS score 56 comparator arm 56 preintervention 56 mammographic density 56 VP# [004] 56 PSADT 56 severe oral mucositis 56 LTBI 56 locoregional 56 Reverset 56 zoledronic acid 56 APTIVUS 56 expressors 56 VIRAMUNE 56 % Confidence Interval 56 pegylated interferon alfa 2b 56 elevated bilirubin 56 5-FU/LV 56 μg dL 56 IFN gamma 56 % CI #.#-#.# [007] 56 spontaneous preterm birth 56 -#.# log# 56 ng dL 56 micafungin 56 grade cervical intraepithelial 56 -#.# log# copies mL 56 HCV viral 56 prostate cancer CaP 56 bolus dose 56 lopinavir r 56 Kaplan Meier estimate 56 MenACWY CRM 56 hsCRP levels 56 antibiotic prophylaxis 56 dexamethasone Decadron 56 serum uric acid 56 Solid Tumors criteria 56 recurrent venous thromboembolism 56 pegylated interferon alpha 56 elvitegravir 56 dapsone 56 FluCAM arm 56 advanced adenoma 56 Crohn Disease Activity 56 MF# adjuvanted 56 Median survival 56 RBC folate 56 aged ≥ 56 NNRTI 56 C. trachomatis 56 intermittent dosing 56 HBV infections 56 pegylated interferon alfa 56 q#d 56 darunavir r 56 ritonavir boosted atazanavir 56 partial remissions 56 BRCA2 mutation carriers 56 perinatal transmission 55 elotuzumab 55 acellular pertussis vaccine 55 febrile seizure 55 dose dexamethasone 55 alteplase 55 pharmacokinetics PK 55 baseline A1C 55 PEG Interferon alfa 55 sero positive 55 FluCAM 55 tumor regressions 55 darunavir 55 desvenlafaxine succinate 55 SCIg 55 interferon ribavirin 55 COPD exacerbation 55 avosentan 55 KRAS status 55 dose cytarabine 55 Immunohistochemical analysis 55 blood phenylalanine Phe 55 prepubertal 55 serodiscordant couples 55 hepatitis B infection 55 reinfarction 55 serum PSA 55 Ad5 55 monoinfected patients 55 biologic DMARD 55 prior relapsers 55 TPV r 55 serum testosterone levels 55 plasma folate 55 ALT elevations 55 DermaVir Patch 55 nadroparin 55 goserelin 55 DAPT 55 peripheral blood mononuclear 55 #q# deletion syndrome 55 alfa 2a 55 HIV infection 55 ceftriaxone 55 aminotransferases 55 vaccine serotypes 55 raltegravir 55 postexposure 55 ORENCIA ® 55 urate lowering therapy 55 HIV coinfected 55 distant metastasis 55 HER2 overexpression 55 serogroup 55 PPSV# 55 ascending doses 55 glomerular filtration 55 enoximone 55 nonvertebral fractures 55 administered subcutaneously 55 anagrelide 55 paraprotein 55 Elitek 55 ug mL 55 QTcF 55 corrected QT interval 55 atheroma volume 55 titres 55 hemoglobin Hb 55 subclinical hypothyroidism 55 3TC lamivudine Epivir 55 Ad5 immunity 55 P = .# 55 severe hyperbilirubinemia 55 #mg BID [002] 55 adrenal suppression 55 ibandronate 55 nadolol 55 Response Evaluation Criteria 55 ALISTA 55 dose regimen 55 PROMACTA 55 clinically meaningful improvement 55 Partial Response 55 microbiological eradication 55 peginterferon alfa 2a #KD 55 rFVIIa 55 telaprevir dosed 55 nonpregnant women 55 secondary efficacy endpoints 55 TransVax TM 55 NHANES III 55 COPEGUS 55 plus ribavirin 55 varicella infection 55 microalbuminuria 55 PROSTVAC VF 55 #mg/day [001] 55 dose Iluvien 55 nadir CD4 cell 55 budesonide foam 55 COMBIVIR 55 tumor regression 55 ml kg 55 pneumococci 55 pneumococcal serotypes 55 HbA1c levels 55 asthma exacerbation 55 serum estradiol 55 μg ml 55 teriflunomide 55 nilotinib 55 low dose ritonavir 55 abnormal Pap smear 55 HepC 55 metastatic RCC 55 MCV4 55 elevated transaminases 55 morphometric vertebral fractures 55 mycophenolate mofetil 55 operable breast cancer 55 valopicitabine 55 Phase Ib clinical 55 PREZISTA ritonavir 55 K#R [002] 55 HPV genotypes 55 gonococcal infections 55 trastuzumab 55 undetectable virus HCV 55 inhibin 55 CK # plasma concentrations 55 nucleoside naive 55 serum phosphorus 55 relapsed MCL 55 prospectively defined 55 initiating HAART 55 mg TID 55 sUA levels 55 cobiprostone 55 receiving VICTRELIS 55 varicella zoster virus 55 CCR5 tropic HIV 55 intramuscularly 55 ug kg 55 leukopenia 55 APOPTONE 55 tumor histology 55 corticosteroid dose 55 thromboembolic events 55 EBRT 55 % CI #.#-#.# [006] 55 CVD mortality 55 JAK2 V#F 55 HbA1C 55 receiving APTIVUS r 55 suppressive therapy 55 glycated hemoglobin HbA1c 55 diphtheria tetanus acellular pertussis 55 Sustained Virological Response 55 Fludara 55 Pharmacokinetic 55 macroalbuminuria 55 alpha 2a 55 T2DM 55 HAI titers 55 atypical ductal hyperplasia 55 mCRC patients 55 immunocompetent 55 comparator PI r 55 concentration Cmax 55 microgram dose 55 RSV hospitalizations 55 RNA copies mL 54 serum ferritin 54 tigecycline 54 K ras mutations 54 telbivudine 54 locoregional disease 54 CIN3 + 54 cells/mm3 54 seliciclib 54 invasive candidiasis 54 transaminase levels 54 doripenem 54 velafermin 54 SHBG levels 54 COPD exacerbations 54 chemoradiotherapy 54 nevirapine Viramune 54 MADRS score 54 retapamulin 54 intradermal injection 54 mcg Albuferon 54 peg interferon 54 hydroxyvitamin D levels 54 bilirubin levels 54 KRAS mutations occur 54 pimecrolimus 54 FOLPI 54 radiographic progression 54 HCV RESPOND 2 54 rebleeding 54 XOMA 3AB 54 Phase #/#a 54 heavily pretreated patients 54 chemoprophylaxis 54 genotype 1a 54 C difficile infection 54 CERVARIX 54 thyrotropin 54 elevated LDH 54 aminotransferase levels 54 ara C 54 FOLFOX4 54 confidence interval CI 54 IV bisphosphonates 54 rotavirus infection 54 insulin detemir 54 disease progression 54 EDSS scores 54 virological suppression 54 thyroglobulin 54 varicella chickenpox 54 HIV HCV coinfected 54 subtrochanteric 54 pharmacokinetic interactions 54 pretest probability 54 dose GATTEX 54 HGPIN 54 Immune responses 54 herpes zoster vaccine 54 tumor shrinkage 54 maternal antibodies 54 anal cancers 54 hemoglobin concentration 54 Immunogenicity 54 T1DM 54 MIRCERA 54 BENICAR HCT 54 Pharmacokinetics PK 54 pharmacodynamic profile 54 NPH insulin 54 epithelial ovarian cancer 54 samalizumab 54 lupus anticoagulant 54 genital herpes infections 54 #mg/m# [002] 54 genital ulcer disease 54 incidence ≥ 54 quadrivalent HPV vaccine 54 S OIV 54 trastuzumab Herceptin ® 54 achieved CCyR 54 dose regimens 54 canakinumab 54 coinfected patients 54 bortezomib refractory 54 IgG antibody 54 YERVOY 54 OGTT 54 RRMS patients 54 FDA defined valvulopathy 54 mesalamine granules 54 tuberculin skin test 54 Free Survival PFS 54 non inferiority 54 dasatinib 54 mg dose 54 apremilast 54 GH deficiency 54 bevirimat 54 tolerability 54 pg ml 54 lamivudine refractory patients 54 eculizumab therapy 54 albumin excretion 54 HAART regimen 54 FOLFOX6 54 antiviral prophylaxis 54 dose titration 54 surface antigen HBsAg 54 elevated creatinine 54 colorectal adenoma 54 virologic breakthrough 54 serum homocysteine 54 circulating lymphocytes 54 androgen suppression 54 CIMZIA TM certolizumab pegol 54 HPV# 54 ACR Pedi 54 p = #.# [003] 54 q8h 54 grade cervical dysplasia 54 intravenous bisphosphonates 54 ORENCIA 54 abnormal cytology 54 chlamydia infection 54 recurrent wheezing 54 d4T stavudine Zerit 54 MACCE 54 MenACWY 54 RECIST criteria 54 HBV 54 CHOP chemotherapy 54 NRTI sparing 54 SIV infection 54 replicon 54 statistical significance p 54 CsA 54 β blockers 54 oral methylnaltrexone 54 endometrial thickness 54 VUR 54 postoperative mortality 54 bacteraemia 54 ritonavir boosted lopinavir 54 BCIRG 54 febrile seizures 54 Baseline characteristics 54 estimated GFR 54 saline placebo 54 hypophosphatemia 54 hematological parameters 54 methotrexate therapy 54 Viramidine 54 antimicrobial prophylaxis 54 glufosfamide 54 mITT population 54 neoadjuvant therapy 54 dexmedetomidine 54 idraparinux 54 Pegylated interferon 54 mCi m 2 54 monotherapy 54 folate concentrations 54 plasma viremia 54 SORT OUT III 54 Betaferon ® 54 sirolimus eluting stent 54 serogroups 54 antitumor effect 54 chloride secretion 54 S. aureus 54 TMC# [001] 54 Partial Responses 54 dosing cohort 54 prophylaxis 54 intracranial hemorrhage ICH 54 μg kg 54 postmenopausal osteoporotic women 54 Flu Cy 54 tolvaptan 54 iPTH 54 Inhibin B 54 mcg doses 54 quinolone resistant 54 grade cervical lesions 54 candidemia 54 PCV7 54 #OHD levels 54 inactivated influenza vaccine 54 pT2 54 hepatorenal syndrome 54 low dose cytarabine 54 Interferon beta 1b 54 IFN α 54 abnormal Pap test 54 ZD# [001] 54 MAGE A3 ASCI 54 reperfusion therapy 54 bortezomib 54 MRSA isolates 54 IL#B 54 serum clusterin levels 54 p = .# [002] 54 aminotransferase ALT 54 infliximab therapy 54 FFNS 54 histologically confirmed 54 creatinine ratio 54 advanced adenomas 54 urine NGAL 54 S. aureus infections 54 RhD negative 54 transaminases 54 antigen PSA levels 54 circulating EPCs 54 boosted protease inhibitor 54 hemoglobin A1c levels 54 Recurrence Score 54 squamous intraepithelial lesions 54 zotarolimus eluting stent 54 oocytes retrieved 54 recurrent miscarriage 54 ritonavir boosted protease inhibitor 54 CD8 T cell 54 chlamydial 54 HbF 54 celgosivir 54 PENNVAX B 54 bendamustine 54 Valcyte 54 intact parathyroid hormone 54 HbA 1c 54 visceral metastases 54 R# #mg BID 54 GARDASIL ® 54 gastric adenocarcinoma 54 abnormal p# biomarker 54 androgen deprivation 54 NNRTIs 54 hip BMD 54 MMRV 54 ascending dose 54 Phase 2a trial 54 thrombotic complications 54 baminercept 54 tPSA 54 rhTSH 54 Platelet counts 54 perioperative mortality 54 chronic HCV genotype 54 REYATAZ ® 54 PREVENT IV 54 degarelix 54 corifollitropin alfa 54 hypogonadal men 54 nonexposed 54 pegylated alpha interferon 54 pT3 54 etanercept 54 randomisation 54 albumin excretion rate 53 trabectedin 53 Folfox 53 DAS# [002] 53 ATACAND 53 VLBW 53 HAART initiation 53 abatacept 53 dose proportionality 53 ddI 53 serologic testing 53 interferon alfa 2b 53 S aureus 53 chronic HCV 53 co trimoxazole 53 nonnucleoside reverse transcriptase inhibitors 53 oral rivaroxaban 53 Subgroup analysis 53 n = 53 RSV bronchiolitis 53 8mg/kg 53 darunavir ritonavir 53 motavizumab 53 cytopenias 53 intrapartum 53 Non inferiority 53 Dasatinib 53 symptomatic intracranial hemorrhage 53 IIIa inhibitors 53 riociguat 53 EGFR TKI 53 intima media thickness 53 ICD implantation 53 pharmacodynamic PD 53 VIRAMUNE XR 53 leukemia AML 53 -#.# ± [002] 53 cervical vulvar 53 variceal bleeding 53 Traficet EN 53 URTI 53 laboratory abnormalities 53 prospectively stratified 53 pegylated liposomal doxorubicin 53 familial AF 53 ovulation suppression 53 Toxicities 53 DTaP 53 estimated glomerular filtration 53 Apgar scores 53 dose limiting toxicities 53 stent thromboses 53 R0 resection 53 Telintra 53 KRAS wild 53 nephrotoxicity 53 IGFBP 53 carboplatin paclitaxel 53 RECIST